Bison Capital Acquisition (Right)

YTD

ALL

Why Robinhood?

You can watch BCACR and buy or sell other stocks, ETFs, and their options commission-free!

About BCACR

Xynomic Pharma focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles.

CEO

Yinglin Mark Xu, MBA

CEOYinglin Mark Xu, MBA

Employees

—

Employees—

Headquarters

Shanghai, Shanghai

HeadquartersShanghai, Shanghai

Founded

2016

Founded2016

Employees

—

Employees—

BCACR Key Statistics

Market cap

—

Market cap—

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

—

Average volume—

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

—

52 Week high—

52 Week low

—

52 Week low—

Stock Snapshot

As of today, Bison Capital Acquisition (Right)(BCACR) shares are valued at $0.42.

On 2025-12-06, Bison Capital Acquisition (Right)(BCACR) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for Bison Capital Acquisition (Right)(BCACR) stock has reached 0.